Rosetta Genomics to Present at 2015 Aegis Growth Conference
October 01 2015 - 8:30AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics,
announces that Company management will participate in the upcoming
2015 Aegis Growth Conference being held from October 7-9, 2015 at
the Encore at Wynn Las Vegas. Kenneth A. Berlin, Rosetta’s
President and Chief Executive Officer, will present a corporate
overview and update on October 8, 2015 at 11:25 a.m. Pacific
Time.
A live audio webcast of Mr. Berlin’s presentation will be
available in the investor section of Rosetta Genomics’ website,
http://www.rosettagenomics.com, where it will also be archived for
90 days
About Rosetta Genomics
Rosetta develops and commercializes a broad range of
microRNA-based and other high-value molecular diagnostics.
Rosetta’s integrative research platform combining bioinformatics
and state-of-the-art laboratory processes has led to the discovery
of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company also offers core FISH, IHC and
PCR-based testing capabilities and partnerships in oncology and
urology that provide additional content and platforms that
complement the Rosetta offerings. Rosetta’s cancer testing services
are commercially available through the Philadelphia, PA- and Lake
Forest, CA-based CAP-accredited, CLIA-certified labs. For more
information visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects including, but not limited
to statements relating to Rosetta Genomics having a
best-in-class FISH testing program, Rosetta Genomics’ testing
turnaround times, Rosetta Genomics enhancing oncologist’s treatment
options and Rosetta Genomics achieving New York State approval for
any or all of its tests, constitute forward-looking statements for
the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including those risks
more fully discussed in the "Risk Factors" section of Rosetta’s
Annual Report on Form 20-F for the year ended December 31,
2014 as filed with the SEC. In addition, any forward-looking
statements represent Rosetta’s views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151001005433/en/
Company:Rosetta GenomicsKen Berlin, 609-419-9003President
& CEOinvestors@rosettagenomics.comorInvestor:LHAAnne
Marie Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024